Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan-based add-on therapy with amlodipine in Chinese patients with essential hypertension inadequately controlled on amlodipine
ChiCTR-ONC-12001963Phase 4Completed
- Sponsor
- Ruijin Hospital
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of olmesartan, amlodipine and hydrochlorothiazide in essential hypertension, sponsored by Ruijin Hospital. Primary endpoint: Responder rate at week 16. Started Dec 2011; status: completed.
02
Drugs
olmesartanamlodipinehydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR-ONC-12001963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12001963.